BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Mylan Inc. (MYL) to Partner with United Nations and Clinton Health Access Initiative to Fight Diarrhea Fatalities in Children in India


4/30/2012 10:22:12 AM

PITTSBURGH and MUMBAI, India, April 28, 2012 /PRNewswire/ -- Mylan Laboratories Limited, the Indian subsidiary of Mylan Inc. (Nasdaq: MYL), today announced that it has entered into a partnership with the United Nation's Millennium Development Goals Health Alliance (MDGHA) and the Clinton Health Access Initiative (CHAI) to fight childhood deaths caused by diarrhea. According to a recent United Nations study, India has the highest number of childhood fatalities per year caused by diarrhea.[1] These unnecessary deaths primarily are attributed to the lack of access to treatments like oral rehydration solution (ORS) and zinc. A recent World Health Organization report estimates that diarrhea is the second leading cause of death globally among children under five.[2]

At a conference conducted in Mumbai on Saturday to discuss how public-private partnerships can be mobilized to advance the health of women and children in India, Mylan announced that it would develop and expand access to ORS and zinc for needy children across the country.

Anirudh Deshpande, Senior Vice President for Business Development of Mylan Laboratories in India, said: "This is a tragic, heartbreaking and avoidable situation that largely can be addressed if these children simply get the treatments they need. At Mylan, we are committed to increasing access to these affordable treatments to the children of India and those in the rest of the world. We share the concerns of organizations such as MDGHA and CHAI about expanding access to these life-saving medicines, and we look forward to continuing to work with them to help meet these needs."

Mylan has played a pioneering role over the past decade in providing innovative therapies that can enhance treatment compliance for HIV/AIDS patients in the developing world. Initiatives such as the development of ORS and zinc for pediatric diarrhea further demonstrate the company's commitment to providing the world's 7 billion people access to high quality medicine. Mylan's wide range of ARV products includes 13 active pharmaceutical ingredients (API) and 42 first- and second-line finished doses, nine of which are pediatric products. The company's emphasis on producing affordable ARV products has helped to drive down the average annual cost per patient of effective therapies.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com or www.mylan.in.

[1] "Vaccines, hygiene could stop diarrhea deaths: U.N." 14 Oct. 2009. Reuters.
http://www.reuters.com/article/2009/10/14/us-diarrhoea-children-idUSTRE59D3L620091014

[2] 2009 WHO Report "Diarrhoea: why children are still dying and what can be done." http://whqlibdoc.who.int/publications/2009/9789241598415_eng.pdf

SOURCE Mylan Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES